08/15/22  Viridian Therapeutics, Inc. (NASDAQ: VRDN) today announced positive initial clinical data from the 10mg/kg cohort in its ongoing Phase 1/2 clinical trial of VRDN-001, an anti-IGF-1R antibody, in patients with active thyroid eye disease (TED).

06/07/22  A Philadelphia life sciences company spun out of a University of Pennsylvania research lab is emerging from stealth mode with nearly $10 million from a seed funding round.

05/03/22  Dianthus Therapeutics, a biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today announced the completion of its $100 million Series A financing led by 5AM Ventures, Avidity Partners, and Fidelity Management & Research Company, with participation from additional investors including Wedbush Healthcare Partners and founding investors Fairmount, Tellus BioVentures, and Venrock Healthcare Capital Partners.